Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26218118 | 0.86 | MEN1 (0.43) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL26218120 | 0.86 | MEN1 (0.43) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL26218117 | 0.86 | MEN1 (0.43) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL23975256 | 0.86 | MEN1 (0.43) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL23594355 | 0.86 | MEN1 (0.43) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL23177661 | 0.85 | ALDH1A1 (0.40) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL23682905 | 0.84 | KDM4E (0.40) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL23975101 | 0.84 | KDM4E (0.38) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL5066367 | 0.84 | MEN1 (0.50) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL22821424 | 0.82 | MEN1 (0.47) | MEN1KMT2AKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | HAVCR2, CUL4A, PSMC3 | MEN1 4716/4885KMT2A 1752/4885KDM4E 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.